St. Vincents Hospital

Sydney, New South Wales 2019

4 studies enrolling now · 26 studies all time

What they study most

Acute Myelogenous Leukemia, Advanced Breast Cancer, Advanced Cancer, Advanced Solid Tumor, Advanced or Metastatic Solid Tumors, Aggressive Lymphoma, Alzheimer Disease, B-cell Acute Lymphoblastic Leukemia, Bile Duct Cancer, Bladder Cancer, Breast Cancer, COVID

Studies at this site

• ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies — Recruiting now
• A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma — Recruiting now
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer — Recruiting now
• DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors — Recruiting now
• Outpatient Treatment With Anti-Coronavirus Immunoglobulin — Paused
• A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease — Completed
• Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer — Running, not enrolling
• NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers — Running, not enrolling
• A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer — Running, not enrolling
• A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Running, not enrolling
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors — Stopped early
• A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer — Stopped early
• NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer — Completed
• The Aortix CRS Pilot Study — Completed
• Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest — Completed
• A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer — Completed
• Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection. — Completed
• Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer — Completed
• Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas — Stopped early
• FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH) — Completed
• ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis — Stopped early
• Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia — Completed
• FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) — Withdrawn before enrolling
• Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis — Completed
• ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH) — Completed